Fosun Capital co-led a round for prostate cancer and gout drug developer Hinova Pharma, which had previously raised capital in 2014 and 2017.
China-based drug developer Hinova Pharma closed a $40m series B round on Monday that was co-led by Fosun Pharmaceutical, the pharmaceuticals producer part-owned by conglomerate Fosun.
Private equity fund Hermed Capital co-led the round, which also featured Lang Sheng Investment, Prosper Capital, Silicon Valley Torch Fund, Chengdu Dingjian New Material Partnership and Hengxing Capital.
Founded in 2013, Hinova Pharma is developing drug treatments for disease areas including cancer and metabolic disorders.
The company’s lead candidate, HC-1119, is set to commence…
